Director Lori Anne Kunkel filed a Form 4 with the SEC on November 3, 2026, disclosing two stock option exercises at Enliven Therapeutics, Inc. (NASDAQ:ELVN) on October 30, 2026.

Key Highlights

  • First transaction: 3,741 shares of common stock were acquired on October 30, 2026 via transaction code M at a price of $1.12 per share.
  • Second transaction: 7,300 shares of common stock were acquired on October 30, 2026 via transaction code M at a price of $18.30 per share.
  • Post-first-transaction holding: Following the 3,741-share acquisition, Kunkel directly held 45,625 shares of common stock.
  • Post-second-transaction holding: Following the 7,300-share acquisition, Kunkel directly held 52,925 shares of common stock.
  • Remaining derivative position: After the second option exercise, Kunkel directly held 30,582 stock options with an exercise price of $18.30 and an expiration date of April 8, 2034.
  • Reporting person's role: Kunkel is identified in the filing as a Director of Enliven Therapeutics, Inc.

Details of Kunkel's October 30, 2026 Option Exercises at Enliven Therapeutics

According to the Form 4 filed on November 3, 2026, Director Lori Anne Kunkel exercised two separate stock options in Enliven Therapeutics, Inc. (NASDAQ:ELVN) on October 30, 2026. The first exercise involved 3,741 shares under a stock option with an exercise price of $1.12 per share, expiring June 15, 2030. The filing notes that "all of the shares subject to this option are fully vested and exercisable as of the date hereof." Following this transaction, Kunkel directly held 45,625 shares of common stock.

The second exercise covered 7,300 shares under a stock option with an exercise price of $18.30 per share, expiring April 8, 2034. The filing states that the option was "originally for 37,882 shares, of which 7,300 shares have been exercised," and that it "vests as to 1/36th of the shares on May 8, 2024 and each month thereafter, subject to the Reporting Person continuing as an outside director through each such date." After this second exercise, Kunkel directly held 52,925 shares of common stock and retained 30,582 stock options with the $18.30 exercise price. Both derivative transactions were reported with a price of $0 in column 8 (Price of Derivative Security) of Table II, as recorded in the filing.

Enliven Therapeutics is a clinical-stage biopharmaceutical company. The Form 4 was signed by Ben Hohl by power of attorney and submitted on November 3, 2026, with October 30, 2026 listed as the date of earliest transaction. The filing was made pursuant to Section 16(a) of the Securities Exchange Act of 1934.

What Was Disclosed

The filing disclosed two stock option exercises by Director Lori Anne Kunkel in Enliven Therapeutics, Inc. on October 30, 2026, covering 3,741 shares at $1.12 and 7,300 shares at $18.30, resulting in a directly held position of 52,925 shares after both transactions.